ES2178896T3 - Nueva forma de sal de pantoprazol. - Google Patents
Nueva forma de sal de pantoprazol.Info
- Publication number
- ES2178896T3 ES2178896T3 ES99941605T ES99941605T ES2178896T3 ES 2178896 T3 ES2178896 T3 ES 2178896T3 ES 99941605 T ES99941605 T ES 99941605T ES 99941605 T ES99941605 T ES 99941605T ES 2178896 T3 ES2178896 T3 ES 2178896T3
- Authority
- ES
- Spain
- Prior art keywords
- pantoprazole
- salt
- comparison
- new form
- exhibits
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 2
- 229960005019 pantoprazole Drugs 0.000 abstract 3
- 238000000354 decomposition reaction Methods 0.000 abstract 2
- RDRUTBCDIVCMMX-UHFFFAOYSA-N magnesium;5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical class [Mg+2].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC.COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC RDRUTBCDIVCMMX-UHFFFAOYSA-N 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000002845 discoloration Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004682 monohydrates Chemical class 0.000 abstract 1
- YNWDKZIIWCEDEE-UHFFFAOYSA-N pantoprazole sodium Chemical compound [Na+].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC YNWDKZIIWCEDEE-UHFFFAOYSA-N 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Detergent Compositions (AREA)
- Manufacture And Refinement Of Metals (AREA)
- Drying Of Gases (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Nueva forma de sal de pantoprazol. La nueva forma de sal se puede emplear en la industria farmacéutica para la preparación de medicamentos. Se ha encontrado ahora que el dihidrato de la sal de magnesio del pantoprazol tiene propiedades de estabilidad muy sorprendentes, que lo hacen aparecer como particularmente apropiado para su uso en formas de administración sólidas o por vía oral. Exhibe propiedades de estabilidad muy considerablemente mejoradas, tanto en comparación con el pantoprazol propiamente dicho como en comparación con el pantoprazol sodio sesquihidrato , o en comparación con el pantoprazol sodio monohidrato Así, el pantoprazol magnesio dihidrato es completamente estable durante 4 días a 90°C y no exhibe casi ninguna descoloración ni descomposición, mientras que los pantoprazol sodio sesquihidrato y monohidrato viran a color rojo pardo en el mismo período de tiempo con formación de cantidades considerables de productos de descomposición.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19843413A DE19843413C1 (de) | 1998-08-18 | 1998-08-18 | Neue Salzform von Pantoprazol |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2178896T3 true ES2178896T3 (es) | 2003-01-01 |
Family
ID=7881823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES99941605T Expired - Lifetime ES2178896T3 (es) | 1998-08-18 | 1999-08-12 | Nueva forma de sal de pantoprazol. |
Country Status (33)
Country | Link |
---|---|
US (2) | US6410569B1 (es) |
EP (1) | EP1105386B1 (es) |
JP (1) | JP2002523411A (es) |
KR (1) | KR100657835B1 (es) |
CN (1) | CN1146558C (es) |
AT (1) | ATE219074T1 (es) |
AU (1) | AU761715B2 (es) |
BG (1) | BG65255B1 (es) |
BR (1) | BR9914288A (es) |
CA (1) | CA2341031C (es) |
CZ (1) | CZ293734B6 (es) |
DE (3) | DE19843413C1 (es) |
DK (1) | DK1105386T3 (es) |
EA (1) | EA004431B1 (es) |
EE (1) | EE04278B1 (es) |
ES (1) | ES2178896T3 (es) |
HK (1) | HK1037616A1 (es) |
HR (1) | HRP20010117B1 (es) |
HU (1) | HU226618B1 (es) |
IL (3) | IL141328A0 (es) |
ME (1) | ME00562A (es) |
MX (1) | MXPA01001758A (es) |
NO (1) | NO319782B1 (es) |
NZ (1) | NZ509761A (es) |
PL (1) | PL198801B1 (es) |
PT (1) | PT1105386E (es) |
RS (1) | RS50071B (es) |
SI (1) | SI1105386T1 (es) |
SK (1) | SK285105B6 (es) |
TR (1) | TR200100287T2 (es) |
UA (1) | UA58605C2 (es) |
WO (1) | WO2000010995A1 (es) |
ZA (1) | ZA200100934B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19843413C1 (de) * | 1998-08-18 | 2000-03-30 | Byk Gulden Lomberg Chem Fab | Neue Salzform von Pantoprazol |
MY137726A (en) | 2000-11-22 | 2009-03-31 | Nycomed Gmbh | Freeze-dried pantoprazole preparation and pantoprazole injection |
TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
DE10234617B4 (de) * | 2002-07-29 | 2013-04-04 | Nycomed Gmbh | Neues Salz von (S)-Pantoprazol |
CA2510849A1 (en) * | 2002-12-19 | 2004-07-08 | Teva Pharmaceutical Industries Ltd | Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates |
AU2004237362A1 (en) * | 2003-05-06 | 2004-11-18 | Altana Pharma Ag | Proton pump inhibitors for the treatment of lower abdominal disorders |
CL2004000983A1 (es) * | 2003-05-08 | 2005-03-04 | Altana Pharma Ag | Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y |
PE20050150A1 (es) * | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo |
CN1791406A (zh) * | 2003-05-19 | 2006-06-21 | 普利瓦研究与发展有限公司 | 5-(二氟甲氧基)-2-[[(3,4-二甲氧基-2-吡啶基)甲基]亚硫酰基]-1h-苯并咪唑(泮托拉唑)钠水络合物的固态形式 |
EP1615913A2 (en) | 2003-06-10 | 2006-01-18 | Teva Pharmaceutical Industries Limited | Process for preparing 2-(pyridinyl)methyl sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole |
WO2005012289A1 (en) * | 2003-07-17 | 2005-02-10 | Altana Pharma Ag | Novel salt of (r) - pantoprazole |
DK1651217T3 (da) * | 2003-07-23 | 2008-06-16 | Nycomed Gmbh | Alkalisalte af protonpumpeinhibitorer |
CN100457104C (zh) * | 2003-07-23 | 2009-02-04 | 尼科梅德有限责任公司 | 质子泵抑制剂的碱性盐 |
CA2554260A1 (en) * | 2004-01-28 | 2005-08-18 | Altana Pharma Ag | Calcium, potassium, zinc, lithium and aluminium salts of pantoprazole and (s)-pantoprazole |
WO2005074898A2 (en) * | 2004-01-28 | 2005-08-18 | Altana Pharma Ag | Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori |
WO2005074932A1 (en) * | 2004-01-28 | 2005-08-18 | Altana Pharma Ag | The use of (s) - pantoprazole magnesium for the treatment of airway disorders |
WO2005074930A1 (en) * | 2004-01-28 | 2005-08-18 | Altana Pharma Ag | Pharmaceutical combinations of (s) -pantoprazole with nsaid or corticosteroids |
WO2005074931A1 (en) * | 2004-01-28 | 2005-08-18 | Altana Pharma Ag | Pharmaceutical combinations comprising (s) -pantoprazole |
EP1716136A1 (en) * | 2004-02-11 | 2006-11-02 | Ulkar Kimya Sanayii Ve Ticaret A.S. | Pyridine benzimidazole sulfoxides of high purity |
WO2005082888A1 (en) * | 2004-03-01 | 2005-09-09 | Milen Merkez Ilac Endustrisi A.S. | Process for the preparation of magnesium salt of omeprazole |
JP2007536349A (ja) * | 2004-05-07 | 2007-12-13 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の医薬剤形及び製造方法 |
WO2007041790A1 (en) * | 2005-10-14 | 2007-04-19 | Jon Pty Limited | Salts of proton pump inhibitors and process for preparing same |
WO2007146341A2 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries Ltd. | Amorphous and crystalline forms of pantoprazole magnesium salt |
WO2008057559A1 (en) * | 2006-11-06 | 2008-05-15 | Teva Pharmaceutical Industries Ltd. | Processes for preparing substantially pure pantoprazole magnesium |
EP3187494A1 (en) * | 2015-12-30 | 2017-07-05 | KRKA, tovarna zdravil, d.d., Novo mesto | Process for the preparation of pantoprazole sodium sesquihydrate |
EP3397630B1 (en) * | 2015-12-30 | 2021-05-26 | KRKA, tovarna zdravil, d.d., Novo mesto | Process for the preparation of pantoprazole sodium sesquihydrate |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
JPS6150978A (ja) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
FI90544C (fi) * | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
DE4018642C2 (de) * | 1990-06-11 | 1993-11-25 | Byk Gulden Lomberg Chem Fab | Neue Salzform des 5-Difluormethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl]-1H-benzimitazol-Natriumsalzes |
YU48263B (sh) * | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
SE508669C2 (sv) * | 1996-04-26 | 1998-10-26 | Astra Ab | Nytt förfarande |
DE19843413C1 (de) * | 1998-08-18 | 2000-03-30 | Byk Gulden Lomberg Chem Fab | Neue Salzform von Pantoprazol |
-
1998
- 1998-08-18 DE DE19843413A patent/DE19843413C1/de not_active Expired - Fee Related
-
1999
- 1999-08-12 DK DK99941605T patent/DK1105386T3/da active
- 1999-08-12 PT PT99941605T patent/PT1105386E/pt unknown
- 1999-08-12 US US09/762,303 patent/US6410569B1/en not_active Expired - Lifetime
- 1999-08-12 RS YUP-113/01A patent/RS50071B/sr unknown
- 1999-08-12 TR TR2001/00287T patent/TR200100287T2/xx unknown
- 1999-08-12 AT AT99941605T patent/ATE219074T1/de active
- 1999-08-12 SI SI9930096T patent/SI1105386T1/xx unknown
- 1999-08-12 BR BR9914288-0A patent/BR9914288A/pt not_active Application Discontinuation
- 1999-08-12 IL IL14132899A patent/IL141328A0/xx unknown
- 1999-08-12 DE DE69901840T patent/DE69901840T2/de not_active Expired - Lifetime
- 1999-08-12 PL PL345993A patent/PL198801B1/pl unknown
- 1999-08-12 ES ES99941605T patent/ES2178896T3/es not_active Expired - Lifetime
- 1999-08-12 CN CNB998098000A patent/CN1146558C/zh not_active Expired - Fee Related
- 1999-08-12 AU AU55156/99A patent/AU761715B2/en not_active Ceased
- 1999-08-12 SK SK236-2001A patent/SK285105B6/sk not_active IP Right Cessation
- 1999-08-12 IL IL14115799A patent/IL141157A0/xx active IP Right Grant
- 1999-08-12 CZ CZ2001621A patent/CZ293734B6/cs not_active IP Right Cessation
- 1999-08-12 DE DE1999601840 patent/DE122005000049I2/de active Active
- 1999-08-12 ME MEP-847/08A patent/ME00562A/xx unknown
- 1999-08-12 EP EP99941605A patent/EP1105386B1/en not_active Expired - Lifetime
- 1999-08-12 EA EA200100208A patent/EA004431B1/ru not_active IP Right Cessation
- 1999-08-12 MX MXPA01001758A patent/MXPA01001758A/es active IP Right Grant
- 1999-08-12 HU HU0103257A patent/HU226618B1/hu not_active IP Right Cessation
- 1999-08-12 EE EEP200100054A patent/EE04278B1/xx unknown
- 1999-08-12 KR KR1020017001911A patent/KR100657835B1/ko not_active IP Right Cessation
- 1999-08-12 CA CA002341031A patent/CA2341031C/en not_active Expired - Lifetime
- 1999-08-12 WO PCT/EP1999/005928 patent/WO2000010995A1/en active IP Right Grant
- 1999-08-12 JP JP2000566268A patent/JP2002523411A/ja active Pending
- 1999-08-12 NZ NZ509761A patent/NZ509761A/en not_active IP Right Cessation
- 1999-12-08 UA UA2001021133A patent/UA58605C2/uk unknown
-
2001
- 2001-01-23 BG BG105173A patent/BG65255B1/bg unknown
- 2001-01-29 IL IL141157A patent/IL141157A/en not_active IP Right Cessation
- 2001-02-02 ZA ZA200100934A patent/ZA200100934B/en unknown
- 2001-02-12 NO NO20010718A patent/NO319782B1/no not_active IP Right Cessation
- 2001-02-16 HR HR20010117A patent/HRP20010117B1/xx not_active IP Right Cessation
- 2001-11-20 HK HK01108172A patent/HK1037616A1/xx not_active IP Right Cessation
-
2002
- 2002-05-01 US US10/135,528 patent/US6686379B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2178896T3 (es) | Nueva forma de sal de pantoprazol. | |
AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
CO5011053A1 (es) | Procedimiento para la produccion de una forma de dosificacion solida que contiene carvedilol e hidroclorotiazida y formas farmaceuticas obtenidas por dicho procedimiento | |
MX173630B (es) | Derivados de aminoacido, procedimiento para su preparacion y su preparacion y medicamento que los contiene | |
ATE478841T1 (de) | Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung | |
AR006678A1 (es) | Derivados de macrolidas triciclicas, una composicion farmaceutica que los contiene, uso de los mismos para preparar medicamentos y procedimientopara su preparacion | |
AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
AR029312A1 (es) | Formas cristalinas de eto2c-ch2-(r)cgl-aze-pab-oh, procesos para su produccion, formulacion farmaceutica, y uso de estos compuestos para la elaboracion de un medicamento. | |
AR030857A1 (es) | Derivados nitroso de difenolaminas, composiciones farmaceuticas que los contienen y su uso en la preparacion de productos medicinales | |
HN1999000183A (es) | Preparado farmaceuticos de moxifloxacina | |
AR021355A1 (es) | Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento | |
AR012125A1 (es) | UNA SAL DE UN COMPUESTO DERIVADO DEL ÁCIDO NAFTIRIDINA CARBOXíLICO , SU USO PARA LA FABRICACIoN DE UN MEDICAMENTO , PROCEDIMIENTO PARA PREPARARLA Y UNA COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE | |
AR037407A1 (es) | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus de tipo ii | |
UY26529A1 (es) | Composición de gliburida. | |
AR019853A1 (es) | Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci | |
AR018862A1 (es) | Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion | |
SE8400332D0 (sv) | Forening for anvendning som mellanprodukt vid framstellning av lekemedel | |
UY25356A1 (es) | Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
AR021843A1 (es) | Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion. | |
AR049651A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo | |
MX9300399A (es) | Derivados heterotriciclicos. | |
ES2171459T3 (es) | Polvo para administracion nasal de farmaco peptidico o proteinaceo. | |
AR060418A2 (es) | Derivados de azolopirimidina, composicion farmaceutica y uso en la fabricacion de un medicamento | |
MX9400165A (es) | Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen. | |
ES2043943T3 (es) | Procedimiento para la preparacion de compuestos con actividad analgesica central. |